🚀 VC round data is live in beta, check it out!
PepGen Valuation Multiples
Discover revenue and EBITDA valuation multiples for PepGen and similar public comparables like Nykode Therapeutics, ProMIS Neurosciences, Genelux, Equillium and more.
PepGen Overview
About PepGen
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Founded
2018
HQ
Employees
81
Website
Sectors
Financials (LTM)
Market Cap
$113M
PepGen Financials
PepGen reported last 12-month revenue of —.
In the same LTM period, PepGen generated had net loss of ($89M).
Revenue (LTM)
PepGen P&L
In the most recent fiscal year, PepGen reported revenue of — and EBITDA of ($88M).
PepGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($88M) | XXX | XXX | XXX |
| Net Profit | ($89M) | XXX | ($90M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PepGen Stock Performance
PepGen has current market cap of $113M.
Market Cap Evolution
PepGen's stock price is $1.64.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $113M | 1.1% | XXX | XXX | XXX | $-1.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPepGen Valuation Multiples
PepGen trades at 0.2x EV/EBITDA.
PepGen Financial Valuation Multiples
As of April 11, 2026, PepGen has market cap of $113M.
Equity research analysts estimate PepGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PepGen has a P/E ratio of (1.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV (current) | ($18M) | XXX | ($18M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| P/E | (1.3x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PepGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PepGen Margins & Growth Rates
PepGen's revenue in the last fiscal year grew by —.
PepGen's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.
PepGen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PepGen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nykode Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ProMIS Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Genelux | XXX | XXX | XXX | XXX | XXX | XXX |
| Equillium | XXX | XXX | XXX | XXX | XXX | XXX |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PepGen M&A Activity
PepGen acquired XXX companies to date.
Last acquisition by PepGen was on XXXXXXXX, XXXXX. PepGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PepGen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPepGen Investment Activity
PepGen invested in XXX companies to date.
PepGen made its latest investment on XXXXXXXX, XXXXX. PepGen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PepGen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PepGen
| When was PepGen founded? | PepGen was founded in 2018. |
| Where is PepGen headquartered? | PepGen is headquartered in United States. |
| How many employees does PepGen have? | As of today, PepGen has over 81 employees. |
| Who is the CEO of PepGen? | PepGen's CEO is James McArthur. |
| Is PepGen publicly listed? | Yes, PepGen is a public company listed on Nasdaq. |
| What is the stock symbol of PepGen? | PepGen trades under PEPG ticker. |
| When did PepGen go public? | PepGen went public in 2022. |
| Who are competitors of PepGen? | PepGen main competitors are Nykode Therapeutics, ProMIS Neurosciences, Genelux, Equillium. |
| What is the current market cap of PepGen? | PepGen's current market cap is $113M. |
| Is PepGen profitable? | No, PepGen is not profitable. |
| What is the current net income of PepGen? | PepGen's last 12 months net income is ($89M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.